CLOV
Clover Health Investments, Corp.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+51/100
Last price
4.62
▼ 0.06 (1.28%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
4.68
Prev close
4.68
Day high
4.69
Day low
4.58
Volume
3.35M
Market cap
$2.44B
P/E (TTM)
—
52W range
1.58 – 5.59
Day trading desk
Gap from prior close
+0.00%
Prior close 4.68
VWAP
4.62
+0.06% from price
Relative volume
1.41×
Normal
Session range
2.62%
4.58 – 4.70
Position in range
33%
Mid range
ATR (14D)
0.20
4.25% of price
Prior day high
4.71
PDH
Prior day low
4.35
PDL
Bid / ask spread
—
Quote not published
Session volume
6.04M
Avg 4.30M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+6.36%
+4.4%
1M
+8.11%
+7.0%
3M
-1.29%
-5.8%
6M
+142.11%
+123.9%
YTD
+95.74%
+81.5%
1Y
+77.61%
+61.2%
3Y
+325.93%
+243.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CLOV open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-1.20M
Net selling
Buy transactions
2
163.04K shares
Sell transactions
26
1.37M shares
Net transactions
+28
Buys less sells
Sell : buy shares
8.4 : 1
Heavily one-sided
Insider-held shares
22.39M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 5, 26 | REYNOSO JAMIE L. Officer |
SELL | 8.75K | $38.67K | Direct |
| Sep 16, 26 | OLDAKOWSKI JOSEPH FRANK Officer |
SELL | 3.17K | $14.71K | Direct |
| Sep 15, 26 | REYNOSO JAMIE L. Officer |
SELL | 9.27K | $44.33K | Direct |
| Sep 15, 26 | WAI CONRAD Officer |
SELL | 300.00K | $1.42M | Indirect |
| Sep 15, 26 | SOARES KAREN Officer |
SELL | 6.85K | $32.72K | Direct |
| Sep 14, 26 | OLDAKOWSKI JOSEPH FRANK Officer |
SELL | 20.00K | $103.20K | Direct |
| Aug 17, 26 | THORNTON JOSEPH CLAY Chief Financial Officer |
SELL | 17.77K | $78.03K | Direct |
| Aug 12, 26 | SOARES KAREN Officer |
STOCK | 108.69K | $0 | Direct |
| Aug 12, 26 | THORNTON JOSEPH CLAY Chief Financial Officer |
STOCK | 54.35K | $0 | Direct |
| Aug 10, 26 | TOY ANDREW Chief Executive Officer |
SELL | 87.80K | $408.26K | Direct |
| Jul 20, 26 | SOARES KAREN Officer |
SELL | 51.70K | $233.17K | Direct |
| Jul 17, 26 | REYNOSO JAMIE L. Officer |
SELL | 4.84K | $21.92K | Direct |
| Jul 15, 26 | REYNOSO JAMIE L. Officer |
SELL | 13.12K | $61.27K | Direct |
| Jul 15, 26 | TOY ANDREW Chief Executive Officer |
SELL | 62.71K | $292.86K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CLINTON CHELSEA |
Director | 602.81K | Stock Award(Grant) |
GARIPALLI VIVEK |
Director and Beneficial Owner of more than 10% of a Class of Security | 1.86M | Conversion of Exercise of derivative security |
KOUZOUKAS DEMETRIOS L |
Director | 605.98K | Stock Award(Grant) |
KUIPERS PETER J |
Chief Financial Officer | 6.35M | Stock Award(Grant) |
PRIEST BRADY PATRICK |
Officer | 2.04M | Sale |
REYNOSO JAMIE L. |
Officer | 2.79M | Sale |
SOARES KAREN |
Officer | 1.61M | Sale |
THORNTON JOSEPH CLAY |
Chief Financial Officer | 1.25M | Sale |
TOY ANDREW |
Chief Executive Officer | 9.46M | Sale |
WAI CONRAD |
Officer | — | Sale |
Fundamentals
Market cap$2.44B
Enterprise value$2.20B
Revenue (TTM)$2.48B
Gross profit$459.13M
EBITDA$-17.96M
Net income$-18.36M
EPS (TTM)$-0.05
Free cash flow$69.05M
Total cash$243.10M
Total debt$0
Book value / share$0.71
Shares outstanding435.44M
Float412.66M
Short % of float5.58%
Dividend yield0.00%
Beta (5Y)2.46
Valuation & profitability ratios
Trailing P/E—
Forward P/E30.67
PEG ratio—
Price / sales—
Price / book6.47
EV / revenue0.89
EV / EBITDA-122.53
Gross margin18.54%
Operating margin3.77%
Profit margin-0.74%
Return on equity-5.10%
Return on assets-1.77%
Debt / equity—
Current ratio1.50
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.92B | $1.37B | $1.26B | $1.10B | +40.3% |
| Operating revenue | $1.89B | $1.34B | $1.24B | $1.08B | +40.7% |
| Cost of revenue | $1.57B | $1.01B | $1.00B | $993.07M | +55.9% |
| Gross profit | $355.90M | $364.80M | $255.95M | $103.48M | -2.4% |
| Selling, general & admin | $439.75M | $408.93M | $440.25M | $482.40M | +7.5% |
| Total operating expense | $441.43M | $410.26M | $435.52M | $390.14M | +7.6% |
| Operating income | -$85.53M | -$45.46M | -$179.56M | -$286.66M | -88.1% |
| Net interest income | $0 | $0 | -$7.00K | -$1.36M | — |
| Pre-tax income | -$85.55M | -$46.27M | -$210.15M | -$254.58M | -84.9% |
| Net income | -$85.55M | -$43.01M | -$213.36M | -$339.57M | -98.9% |
| Net income to common | -$85.55M | -$43.01M | -$213.36M | -$339.57M | -98.9% |
| Basic EPS | -0.17 | -0.08 | -0.44 | -0.71 | -112.5% |
| Diluted EPS | -0.17 | -0.08 | -0.44 | -0.71 | -112.5% |
| EBIT | -$85.55M | -$46.27M | -$210.14M | -$253.22M | -84.9% |
| EBITDA | -$83.86M | -$44.94M | -$207.63M | -$252.03M | -86.6% |
| Basic shares | 511.97M | 490.02M | 482.18M | 476.24M | +4.5% |
| Diluted shares | 511.97M | 490.02M | 482.18M | 476.24M | +4.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $78.30M | $194.54M | $116.41M | $103.79M | — | -59.8% |
| Cash & short-term investments | $120.26M | $221.56M | $236.23M | $334.76M | — | -45.7% |
| Total current assets | $307.86M | $343.12M | $427.97M | $625.00M | — | -10.3% |
| Property, plant & equipment | $6.38M | $5.31M | $5.08M | $9.78M | — | +20.3% |
| Goodwill & intangibles | $2.99M | $2.99M | $2.99M | $20.00M | — | 0.0% |
| Total assets | $541.01M | $580.74M | $570.67M | $808.62M | — | -6.8% |
| Total current liabilities | $208.82M | $213.52M | $261.12M | $431.51M | — | -2.2% |
| Long-term debt | — | — | — | — | $19.94M | — |
| Total debt | — | — | $4.66M | $5.86M | $27.83M | — |
| Total liabilities | $232.31M | $239.60M | $284.28M | $451.73M | — | -3.0% |
| Retained earnings | -$2.29B | -$2.20B | -$2.16B | -$1.95B | — | -3.9% |
| Shareholder equity | $308.70M | $341.14M | $286.39M | $356.89M | — | -9.5% |
| Working capital | $99.03M | $129.61M | $166.85M | $193.49M | — | -23.6% |
| Net tangible assets | $305.71M | $338.15M | $283.40M | $336.89M | — | -9.6% |
| Shares issued | 552.45M | 522.28M | 496.96M | 480.47M | — | +5.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$85.55M | -$43.01M | -$213.36M | -$339.57M | -98.9% |
| Depreciation & amortisation | $1.69M | $1.33M | $2.51M | $1.19M | +26.7% |
| Stock-based compensation | $103.66M | $114.33M | $140.93M | $164.31M | -9.3% |
| Change in working capital | -$84.20M | $12.86M | $25.29M | -$2.36M | -755.0% |
| Operating cash flow | -$66.93M | $34.84M | -$144.66M | -$203.93M | -292.1% |
| Capital expenditure | -$2.04M | -$1.56M | -$584.00K | -$4.47M | -31.3% |
| Investing cash flow | $4.08M | $565.00K | $140.01M | $95.13M | +621.4% |
| Share buybacks | -$55.20M | -$18.26M | -$6.22M | -$6.36M | -202.2% |
| Financing cash flow | -$53.38M | -$17.36M | -$5.07M | -$4.96M | -207.5% |
| Free cash flow | -$68.98M | $33.29M | -$145.25M | -$208.39M | -307.2% |
| End cash position | $78.30M | $194.54M | $176.49M | $186.21M | -59.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $743.17M | $749.19M | $487.71M | $496.65M | $477.62M | -0.8% |
| Operating revenue | $737.77M | $744.19M | $485.87M | $479.13M | $469.83M | -0.9% |
| Cost of revenue | $590.16M | $589.65M | $413.50M | $423.47M | $377.99M | +0.1% |
| Gross profit | $153.00M | $159.54M | $74.21M | $73.18M | $99.63M | -4.1% |
| Selling, general & admin | $124.44M | $131.69M | $123.11M | $97.15M | $109.79M | -5.5% |
| Total operating expense | $125.00M | $132.21M | $123.53M | $97.55M | $110.19M | -5.5% |
| Operating income | $28.00M | $27.33M | -$49.32M | -$24.38M | -$10.56M | +2.4% |
| Pre-tax income | $28.00M | $27.33M | -$49.32M | -$24.38M | -$10.58M | +2.4% |
| Net income | $28.00M | $27.33M | -$49.32M | -$24.38M | -$10.58M | +2.4% |
| Net income to common | $28.00M | $27.33M | -$49.32M | -$24.38M | -$10.58M | +2.4% |
| Basic EPS | 0.05 | 0.05 | -0.10 | -0.05 | -0.02 | 0.0% |
| Diluted EPS | 0.05 | 0.05 | -0.10 | -0.05 | -0.02 | 0.0% |
| EBIT | $28.00M | $27.33M | -$49.34M | -$24.38M | -$10.56M | +2.4% |
| EBITDA | $28.57M | $27.85M | -$48.92M | -$23.97M | -$10.16M | +2.6% |
| Basic shares | 524.19M | 522.18M | 517.24M | 512.74M | 509.04M | +0.4% |
| Diluted shares | 545.45M | 532.50M | 517.24M | 512.74M | 509.04M | +2.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $198.84M | $173.26M | $78.30M | $190.06M | $188.65M | +14.8% |
| Cash & short-term investments | $243.10M | $203.54M | $120.26M | $202.84M | $201.27M | +19.4% |
| Total current assets | $485.45M | $448.02M | $307.86M | $330.92M | $362.94M | +8.4% |
| Property, plant & equipment | $7.23M | $6.90M | $6.38M | $5.49M | $5.20M | +4.7% |
| Goodwill & intangibles | $2.99M | $2.99M | $2.99M | $2.99M | $2.99M | 0.0% |
| Total assets | $720.33M | $697.73M | $541.01M | $559.66M | $574.99M | +3.2% |
| Total current liabilities | $323.33M | $336.58M | $208.82M | $193.45M | $201.95M | -3.9% |
| Total liabilities | $344.07M | $358.30M | $232.31M | $218.73M | $230.81M | -4.0% |
| Retained earnings | -$2.23B | -$2.26B | -$2.29B | -$2.24B | -$2.21B | +1.2% |
| Shareholder equity | $376.26M | $339.43M | $308.70M | $340.93M | $344.18M | +10.9% |
| Working capital | $162.12M | $111.44M | $99.03M | $137.47M | $160.99M | +45.5% |
| Net tangible assets | $373.27M | $336.44M | $305.71M | $337.94M | $341.19M | +10.9% |
| Shares issued | 529.15M | 560.25M | 552.45M | 544.46M | 538.89M | -5.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $28.00M | $27.33M | -$49.32M | -$24.38M | -$10.58M | +2.4% |
| Depreciation & amortisation | $564.00K | $515.00K | $420.00K | $406.00K | $394.00K | +9.5% |
| Stock-based compensation | $9.08M | $12.27M | $24.92M | $26.11M | $26.20M | -26.0% |
| Change in working capital | -$11.71M | $68.10M | -$42.86M | $10.17M | -$9.53M | -117.2% |
| Operating cash flow | $25.19M | $107.89M | -$68.15M | $12.10M | $5.41M | -76.7% |
| Capital expenditure | -$682.00K | -$854.00K | -$597.00K | -$692.00K | -$569.00K | +20.1% |
| Investing cash flow | -$32.00K | -$5.07M | -$34.99M | -$5.42M | $35.57M | +99.4% |
| Share buybacks | -$1.79M | -$7.89M | -$9.20M | -$5.58M | -$8.47M | +77.4% |
| Financing cash flow | $416.00K | -$7.86M | -$8.61M | -$5.27M | -$7.76M | +105.3% |
| Free cash flow | $24.51M | $107.04M | -$68.75M | $11.41M | $4.84M | -77.1% |
| End cash position | $198.84M | $173.26M | $78.30M | $190.06M | $188.65M | +14.8% |
Options analytics
Put / call volume
0.59
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
0.50
-89.1% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+25.0%
Puts bid over calls
Call volume
1.80K
Contracts, this expiry
Put volume
1.06K
Contracts, this expiry
Heaviest call OI
0.50
0 contracts
Heaviest put OI
0.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.05 | 0.07 | +48.0% |
| Mar 2026 | 0.07 | 0.07 | +6.6% |
| Dec 2025 | -0.05 | -0.05 | +8.2% |
| Sep 2025 | 0.02 | 0.00 | -83.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.01 | 1 | $738.18M | +48.6% |
| Next quarter | -0.02 | 1 | $723.47M | +48.3% |
| Current year | 0.14 | 1 | $2.95B | +53.5% |
| Next year | 0.15 | 1 | $3.53B | +19.3% |
Analyst targets & ownership
Mean target$5.38
High target$6.00
Low target$5.00
Implied upside16.34%
Analyst count4
ConsensusNONE
Strong buy / Buy0 / 2
Hold2
Sell / Strong sell0 / 0
Held by insiders4.22%
Held by institutions33.97%
Institutions holding293
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.44
+4.00% from price
SMA 20
4.54
+1.29% from price
SMA 50
4.40
+4.49% from price
SMA 100
4.43
+4.35% from price
SMA 200
3.35
+37.28% from price
EMA 12
4.48
+3.21% from price
EMA 26
4.46
+3.51% from price
EMA 50
4.42
+4.49% from price
RSI (14)
54.7
Neutral
MACD (12,26,9)
0.01
Hist 0.00
ATR (14)
0.20
4.27% of price
Realised vol 30D
51.1%
Annualised
Bollinger upper
4.94
20, 2σ
Bollinger lower
4.14
20, 2σ
50 / 200 cross
Golden
4.40 vs 3.35
Trend bias
Above 200
+37.28%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.27
More volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
51.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-55.5%
Peak to trough
Max drawdown 5Y
-92.3%
Peak to trough
ATR 14
0.20
4.27% of price
Beta (reported)
2.46
5Y monthly, from filing
Short interest
Shares short
23.45M
Prior 26.14M
Change vs prior
-10.3%
Shorts covering
% of float
5.58%
Normal
% of shares out
4.41%
Against total outstanding
Days to cover
5.9
Crowded exit
Float
412.66M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 6, 26 | UBS | MAINTAINED | Neutral | Neutral |
| Jul 21, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jun 11, 26 | UBS | MAINTAINED | Neutral | Neutral |
| Jun 4, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Mar 20, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Mar 5, 26 | Leerink Partners | MAINTAINED | Market Perform | Market Perform |
| Jan 20, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Nov 6, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Aug 7, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Aug 6, 25 | UBS | MAINTAINED | Neutral | Neutral |
| Mar 3, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Dec 17, 24 | Craig-Hallum | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K/A · 2026-09-25
Corporate Changes & Voting Matters
8-K · 2026-09-24
Corporate Changes & Voting Matters
8-K · 2026-08-20
Periodic Financial Reports
10-Q · 2026-08-07
Corporate Changes & Voting Matters
8-K · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-07-17
Corporate Changes & Voting Matters
8-K · 2026-06-18
Corporate Changes & Voting Matters
8-K · 2026-06-16
Headlines
Clover Health Investments (CLOV) Unveils 2027 Medicare Plans, Is The Stock Still Cheap?
Simply Wall St. · 3d ago
3 Great Healthcare Stocks To Own In October 2026
Simply Wall St. · 5d ago
1 Small-Cap Stock to Own for Decades and 2 Facing Headwinds
StockStory · 6d ago
Clover Health’s 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value
GlobeNewswire · 6d ago
1 Cash-Producing Stock on Our Buy List and 2 We Ignore
StockStory · 12d ago
UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D. to Its Board of Directors
GlobeNewswire · 12d ago
Clover Health Welcomes Former U.S. Senator Robert Torricelli and MedPAC Commissioner Dr. Brian J. Miller M.D. to Its Board of Directors
GlobeNewswire · 12d ago
NIO Stock And 2 Penny Stocks To Watch
Simply Wall St. · 14d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.